Part 3. Imatinib for Chronic Myeloid Leukemia (CML) (continued)
Included Articles
1. Al-Ali HK, Krahl R, Orth M, et al. Persistently increased creatine kinase levels in patients with chronic myeloid leukemia treated with imatinib correlate with major cytogenetic remission. Blood 2004;104(11):Abstract #2933.
2. Albitar M, Cortes J, Giles F, et al. Molecular monitoring of chronic phase chronic myeloid leukemia patients treated with 800mg imatinib. Journal of Clinical Oncology 2005;23:Abstract 6554.
3. American Cancer Society. Cancer Facts and Figures 2005.
http://www.cancer.org/docroot/STT/stt_0.asp. Accessed March 25.
4. Anonymous. Interferon alfa versus chemotherapy for chronic
myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid
Leukemia Trialists' Collaborative Group. Journal of the National Cancer
Institute 1997;89(21):1616-20.
5. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated
human recombinant interferon-{alpha}2b in early chronic-phase chronic myeloid
leukemia. Blood 2004;104(13):4245-51.
6. Baccarani M, Rosti G, de Vivo A, et al. Arandomized study
of interferon-a versus interferon-a and low-dose arabinosyl cytosine in chronic
myeloid leukemia. Blood 2002;99:527-1535.
7. Bacik J, Mazumdar M, Murphy B, et al. The functional assessment
of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality
of life in patients treated with biologic response modifiers. Quality of
Life Research 2004;13(1):137-54.
8. Barrett A, Malkovska V. Graft-versus-leukaemia: understanding
and using the alloimmune response to treat haematological malignancies. British
Journal of Haematology 1996;93. 1996:754-61.
9. Bassi S, Castagnetti F, Amabile M, et al. Imatinib in the
treatment of CML patients >65 years old in late chronic phase: Results of
a phase II study of the GIMEMA CML Working Party. Blood 2004;104(11):Abstract #2935.
10. Berger U, Hochhaus A, Reiter A, et al. Feasibility of imatinib
combination therapies in a randomized trial for chronic myeloid leukemia: The
German CML-Study IV-Pilot Phase. Blood 2004;104(11):Abstract #24.
11. Bhatia R., Holtz M., Niu N., et al. Persistence of malignant
hematopoietic progenitors in chronic myelogenous leukemia patients in complete
cytogenetic remission following imatinib mesylate treatment. Blood 2003;101(12):4701-7.
12. Bose S, Deininger MW, Gora-Tybor J, et al. The presence
of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals:
Biologic
significance
and implications for the assessment of minimal residual disease. Blood 92.
1998.
13. Branford S, Rudzki Z, Grigg A, et al. The frequency of
detection of BCR-ABL mutations in imatinib treated patients with chronic phase
CML who attain a
complete cytogenetic response (CCR) does not diminish with increasing duration
of ccr but the associated loss of response is usually gradual. Blood 2004;104(11):Abstract #271.
14. Branford S, Rudzki Z, Grigg A, et al. BCR-ABL levels continue
to decrease up to 42 months after commencement of standard dose imatinib in
patients with
newly diagnosed chronic phase CML who achieve a major molecular response. Blood
2004;104(11):Abstract #274.
15. Branford S, Rudzki Z, Harper A, et al. Imatinib produces
significantly superior molecular responses compared to interferon alfa plus
cytarabine in
patients
with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17(12):2401-9.
16. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative
PCR analysis can be used as a primary screen to identify patients with CMLtreated
with imatinib
who have BCR-ABL kinase domain mutations. Blood 2004;104(9):2926-32.
17. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic
and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia
patients:
14 months' experience. Blood 2002;100(2):435-41.
18. Ceglarek BB, Konopka LJ, Sikorska A, et al. Gleevec Therapy
in Advanced Phases of the CML-Polish Study Report. Blood 2004;104(11):Abstract #4701.
19. Cervantes F, Hernandez-Boluda JC, Odriozola J, et al. Imatinib
mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous
leukaemia
previously
submitted to autologous stem cell transplantation. British Journal of Haematology
2003;120(3):500-4.
20. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration
Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets
from Accelerated
Approval to Full Approval. Clinical Cancer Research 2005;11:12-9.
21. Cohen MH, Williams G, Johnson JR, et al. Approval summary
for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical
Cancer
Research 2002;8(5):935-42.
22. Conneally E, Carroll P, Neat M, et al. Imatinib mesylate
treatment of patients with chronic myeloid leukaemia relapsing following allogeneic
stem
cell transplantation.
Blood 2004;104(11):Abstract #4659.
23. Corm S, Nicollini F, Borie D, et al. Mutation status of
imatinib mesylate-resistants cml patients and clinical outcomes: A French multicenter
retrospective study
for the fiLMC Group. Blood 2004;104(11):Abstract #275.
24. Cornelissen JJ, Valk P, Verhoef GEG, et al. High rates of
molecular response and low incidence of mutations in patients treated with
newly diagnosed chronic
myeloid leukemia (CML) treated with a dose-escalated combination of imatinib
and cytarabin. Blood 2004;104(11):Abstract #19.
25. Corsetti MT, Beltrami G, Carella AM. Imatinib achieves high
rates of complete citogenetic remission (CCR) in CML patients relapsed after
autografting and
IFN-a Therapy. Blood 2004;104(11):Abstract #4656.
26. Cortes J, Giles F, O'Brien S, et al. Result of high-dose
imatinib mesylate in patients with Philadelphia chromosome-positive chronic
myeloid leukemia
after failure of interferon-alpha. Blood 2003;102(1):83-6.
27. Cortes J, Giles F, Salvado A, et al. High dose (HD) imatinib
in patients with previously untreated chronic myeloid leukemia (CML) in early
chronic phase
(CP): preliminary results of a multicenter community based trial. Journal
of Clinical Oncology 2005;20(162):abstract 6518.
28. Cortes J, Talpaz M, Beran M, et al. Philadelphia chromosome-negative
chronic myelogenous leukemia with rearrangement of the breakpoint cluster region.
Long-term
follow-up results. Cancer 1995 Jan 15;75. 1995:464-70.
29. Cortes J, Talpaz M, Giles F, et al. Prognostic significance
of cytogenetic clonal evolution in patients with chronic myelogenous leukemia
on imatinib
mesylate therapy. Blood 2003;101(10):3794-800.
30. Cortes J, Talpaz M, O'Brien S, et al. Survival advantage
for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase
(AP) treated
with
imatinib. Blood 2004;104(11):Abstract #1006.
31. Cortes J, Talpaz M, O'Brien S, et al. High-dose imatinib
mesylate treatment in patients (pts) with previously untreated early chronic
phase (CP) chronic
myeloid leukemia (CML). Blood 2004;104(11):Abstract #999.
32. Cortes J, Talpaz M, O'Brien S, et al. Clinical significance
of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase
(CP) with imatinib
therapy.
Blood 2004;104(11):Abstract #272.
33. Crossman LC, Druker BJ, Deininger MW. hOCT 1 and resistance
to imatinib.
Blood 2005;106(3):1133-4.
34. Crossman LC, Mori M, Hsieh Y, et al. In chronic myeloid
leukemia white cells from cytogenetic responders and non-responders to imatinib
have
very
similar
gene expression signatures. Haematologica 2005;90:459-64.
35. Deininger MW, Willis S, Lange T, et al. Detection of imatinib-resistant
BCR-ABL mutants in drug-naïve patients: correlation with disease phase
and clonal evolution but not with response to treatment. Blood 2004;104(11):Abstract #273.
36. Deshmukh CD, Saikia T, Bakshi AV, et al. Imatinib mesylate
in chronic myeloid leukemia (CML): A single institution experience of 174 patients. Journal
of
Clinical Oncology 2004;22(14S):Abstract #6710.
37. Druker BJ. Taking aim at Ewing's sarcoma: is KIT a target
and will imatinib work? Journal of the National Cancer Institute 2002;94(22):1660-1.
38. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of
a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of
chronic
myeloid leukemia
and acute lymphoblastic leukemia with the Philadelphia chromosome. New England
Journal of Medicine 2001;344(14):1038-42.
39. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety
of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New
England Journal
of Medicine 2001;344(14):1031-7.
40. Drummond A, Micallef-Eynaud P, Douglas WS, et al. A spectrum
of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate
(STI 571, Glivec).
British Journal of Haematology 2003;120(5):911-3.
41. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of
imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia
chromosome.
British Journal of Haematology 2004;125(2):187-95.
42. Elliot VJ, Marin D, Horncastle D, et al. Total number of
CD34 + cells per ten high power fields in bone marrow trephines of patients
with chronic
myeloid
leukaemia correlates with probability of complete cytogenetic response during
the first year of treatment with imatinib. Blood 2004;104(11):Abstract #4664.
43. Faderl S, Talpaz M, Estrov Z, et al. Chronic Myelogenous
leukemia: biology and therapy. Annals of Internal Medicine 1999;131(3):207-19.
44. Fischer T, Reifenrath C, Hess GR, et al. Safety and efficacy
of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous
leukemia
(CML)
after autologous peripheral Blood stem cell transplantation (PBSCT). Leukemia
2002;16(7):1220-8.
45. Frater JL, Tallman MS, Variakojis D, et al. Chronic myeloid
leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology
and correlation
with genetic status. American Journal of Clinical Pathology 2003;119(6):833-41.
46. Fruehauf, Topaly, Buss EC, et al. A multicenter phase I/II
trial of the combination of imatinib mesylate with mitoxantrone/etoposide and
cytarabine
in patients
with CML in myeloid blast crisis: a trend to a longer survival in patients
receiving more aggressive treatment schedules. Blood 2004;104(11):Abstract #2929.
47. Gardembas M, Rousselot P, Tulliez M, et al. Results of a
prospective phase 2 study combining imatinib mesylate and cytarabine for the
treatment of Philadelphia-positive
patients with chronic myelogenous leukemia in chronic phase. Blood 2003;102(13):4298-305.
48. George S, Horvath L, Molokie R, et al. Response to therapy
with imatinib mesylate in patients with CML is poor in non-caucasian patients. Blood 2004;104(11):Abstract #2937.
49. Goldman J. M. , Melo J. V. Mechanisms of disease - Chronic
myeloid leukemia - Advances in biology and new approaches to treatment. New
England Journal of Medicine 2003;349(15):1451-64.
50. Gorre ME, Skaggs BJ, Sawyers CL. Imatinib-resistant BCR-ABL
mutations alter oncogenic potency, kinase activity and substrate selection. Blood 2004;104(11):Abstract #556.
51. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation
for chronic myeloid leukemia. Working Party Chronic Leukemia of the European
Group for
Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation 17
(Suppl 3):S7-9.
52. Guilhot F. Sustained durability of responses plus high rates
of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase
chronic
myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the
IRIS study. Blood 2004;104(11):Abstract #21.
53. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b
combined with cytarabine versus interferon alone in chronic myelogenous leukemia.
French
Chronic Myeloid Leukemia Study Group. New England Journal of Medicine 1997;337(4):223-9.
54. Hahn EA, Glendenning GA. Quality of life on imatinib. Seminars
in Hematology
2003;40(2 Suppl 2):31-6.
55. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of
life in patients with newly diagnosed chronic phase chronic myeloid leukemia
on
imatinib versus
interferon
alfa plus low-dose cytarabine: results from the IRIS Study. Journal of Clinical
Oncology 2003;21(11):2138-46.
56. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic
score for survival of patients with chronic myeloid leukemia treated with interferon
alfa. Writing
Committee for the Collaborative CML Prognostic Factors Project Group. Journal
of the National Cancer Institute 1998;90:850-8.
57. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison
of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of
survival by
hydroxyurea. The German CML Study Group. Blood 1993;82(2):398-407.
58. Hehlmann R, Hochhaus A, Berger U, et al. Concept and feasibility
of the randomized comparison of imatinib with imatinib combination therapies
for chronic
myeloid
leukemia: the German CML Study IV-Pilot Phase. Journal of Clinical Oncology
2005;23(16S):Abstract #6574.
59. Hess G, Bunjes D, Siegert W, et al. Durable molecular remissions
in patients with relapsed CML post allogeneic stem cell transplantation upon
treatment
with imatinib-mesylate (Glivec®, STI-571). Follow-up results of a phase
II open-label study. Blood 2004;104(11):Abstract #1004.
60. Hochhaus A. Imatinib mesylate (Glivec, Gleevec) in the treatment
of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Annals
of Hematology 2004;83(Suppl 1):S65-6.
61. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal
mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16(11):2190-6.
62. Hughes T, Branford S, Reynolds J, et al. Higher-dose imatinib
(600 mg/day) with selective intensification in newly diagnosed CML patients
in chronic phase;
cytogenetic response rates at 12 months are superior to IRIS. Blood 2004;104(11):Abstract #1001.
63. Hughes TP, Kaeda J, Branford S, et al. Frequency of major
molecular responses to imatinib or interferon alfa plus cytarabine in newly
diagnosed chronic myeloid
leukemia. New England Journal of Medicine 2003;349(15):1423-32.
64. Huntly B, Bench A, Delabesse E, et al. Derivative chromosome
9 deletions in chronic myeloid leukemia: poor prognosis is not associated with
loss of
ABL-BCR
expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002;99(12):4547-53.
65. Huntly B, Guilhot F, Reid A, et al. Imatinib improves but
may not fully reverse the poor prognosis of patients with CML with derivative
chromosome
9 deletions.
Blood 2003;102(6):2205-12.
66. Huntly B, Reid A, Bench A, et al. Deletions of the derivative
chromosome 9 occur at the time of the Philadelphia translocation and provide
a powerful
and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98(6):1732-8.
67. Huntly BBA, Green A. Double jeopardy from a single translocation:
deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102(4):1160-8.
68. Issa S, Holdsworth D, Oei P, et al. The utility of peripheral
Blood FISH in the quantitation of BCR/ABL in CML patients on imatinib mesylate:
a comparison
with bone marrow FISH and conventional cytogenetics. Blood 2004;104(11):Abstract #2942.
69. Jabbour E, Kantarjian H, Jones D, et al. Long-term incidence
and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia
(CML)
treated
with imatinib mesylate. P-Loop mutations are not associated with worse outcome.
Blood 2004;104(11):Abstract #1007.
70. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular
genetic evolution of chronic myeloid leukemia. Acta Haematologica 2002;107(2):76-94.
71. Johnson JR, Bross P, Cohen M, et al. Approval summary: imatinib
mesylate capsules for treatment of adult patients with newly diagnosed philadelphia
chromosome-positive
chronic myelogenous leukemia in chronic phase. Clinical Cancer Research 2003;9(6):1972-9.
72. Kagami Y, Katagiri T, Kaneta Y, et al. Validation study
on the prediction of response to imatinib mesylate in chronic myeloid leukemia
(CML) patients
by genome-wide cDNA microarray analysis. Blood 2004;104(11):Abstract #2946.
73. Kaneta Y, Kagami YKT, Tsunoda T, et al. Prediction of sensitivity
to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray
analysis.
Japanese Journal of Cancer Research 2002;93:849–856.
74. Kantarjian H, Cortes J, O'Brien S, et al. Long-term survival
benefit and improved complete cytogenetic and molecular response rates with
imatinib mesylate
in
Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after
failure of interferon-alpha. Blood 2004;104(7):1979-88.
75. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate
(STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia
in blast
phase. Blood 2002;99(10):3547-53.
76. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate
therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic
myelogenous
leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
77. Kantarjian H, Deisseroth A, Kurzrock R, et al. Chronic myelogenous
leukemia: a concise update. Blood 1993;82(3):691-703.
78. Kantarjian H, Dixon D, Keating M, et al. Characteristics
of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61(7):1441-6.
79. Kantarjian H, Keating M, Estey E, et al. Treatment of advanced
stages of Philadelphia chromosome-positive chronic myelogenous leukemia with
interferon-ei
and low-dose
cytarabine. Journal of Clinical Oncology 1992;10(5):772-8.
80. Kantarjian H, O'Brien S, Cortes J, et al. Complete cytogenetic
and molecular responses to interferon-alpha-based therapy for chronic myelogenous
leukemia
are associated with excellent long-term prognosis. Cancer 2003;94(7):1033-41.
81. Kantarjian H, O'Brien S, Cortes J, et al. Imatinib mesylate
therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive
chronic myelogenous leukemia in the chronic phase: comparison with historic
data. Cancer 2003;98(12):2636-42.
82. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage
with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia
(CML-CP) after
IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical Cancer Research 2004;10(1 Pt 1):68-75.
83. Kantarjian H, O'Brien S, Cortes J, et al. Imatinib mesylate
therapy for relapse after allogeneic stem cell transplantation for chronic
myelogenous
leukemia.
Blood 2002;100(5):1590-5.
84. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic
and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New
England Journal of
Medicine 2002;346(9):645-52.
85. Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesylate
for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after
failure of interferon-alpha:
follow-up results. Clinical Cancer Research 2002;8(7):2177-87.
86. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib
mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic
phase chronic
myeloid
leukemia. Blood 2004;103(8):2873-8.
87. Kantarjian H, Talpaz M, O'Brien S, et al. Dose escalation
of imatinib mesylate can overcome resistance to standard-dose therapy in patients
with
chronic myelogenous
leukemia. Blood 2003;101(2):473-5.
88. Kurzrock R, Gutterman J, Talpaz M. The molecular genetics
of Philadelphia chromosome-positive leukemias. New England Journal of Medicine 1988;319(15):990-8.
89. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone
marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate
(STI571) therapy. Blood
2004;103(9):3549-51.
90. Lahaye T, Riehm B, Berger U, et al. Response and resistance
in 300 patients with BCR-ABL–positive leukemias treated with imatinib
in a single center: a 4.5-year follow-up. Cancer 2005;103(8):1659-69.
91. Lange T, Bumm T, Mueller M, et al. Durability of molecular
remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic
stem
cell transplantation.
Leukemia 2005;19:1262-9.
92. Lange T, Bumm T, Mueller M, et al. Molecular remission to
imatinib in patients with chronic myeloid leukaemia (CML) is less durable compared
to patients
after
allografting. Blood 2004;104(11):Abstract #276.
93. Lange T, Gunther C, Kohler T, et al. High levels of BAX,
low levels of MRP-1, and high platelets are independent predictors of response
to imatinib
in myeloid
blast crisis of CML. Blood 2003;101(6):2152-5.
94. Laurence A, Marin D, Clark R, et al. Frequency of blast
crisis after achieving complete cytogenetic remission in first chronic phase
CML patients
who received
imatinib therapy within six months of diagnosis. Blood 2004;104(11):Abstract #1021.
95. Le Coutre P, Kreuzer KA, Na IK, et al. Imatinib in Philadelphia
chromosome-positive chronic phase CML patients: molecular and cytogenetic response
rates and prediction
of clinical outcome. American Journal of Hematology 2003;73(4):249-55.
96. Lee S, Anasetti C, Horowitz M, et al. Initial therapy for
chronic myelogenous leukemia: playing the odds. Journal of Clinical Oncology 1998;16(9):2897-903.
97. Marin D, Goldman JM, Olavarria E, et al. Transient benefit
only from increasing the imatinib dose in CML patients who do not achieve complete
cytogenetic remissions
on conventional doses. Blood 2003;102(7):2702-4.
98. Marin D, Horncastle D, Andreasson C, et al. Prognostic impact
of percentage cd34 expression in bone marrow trephines of patients with chronic
myeloid leukaemia
in chronic phase treated with imatinib. Blood 2004;104(11):Abstract #1019.
99. Marin D, Marktel S, Bua M, et al. Prognostic factors for
patients with chronic myeloid leukaemia in chronic phase treated with imatinib
mesylate after
failure
of interferon alfa. Leukemia 2003;17(8):1448-53.
100. Marin D, Marktel S, Szydlo R, et al. Survival of patients
with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon
alfa. Lancet
2003;362:617-9.
101. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia
in chronic phase responding to imatinib: the occurrence of additional cytogenetic
abnormalities
predicts disease progression. Haematologica 2003;88(3):260-7.
102. Martiat P, Michaux J, Rodhain J. Philadelphia-negative
(Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic
leukemia.
The Groupe Francais de Cytogenetique Hematologique. Blood 1991;78(1):205-11.
103. Martino B, Vincelli Y, Ronco F, et al. Efficacy and safety
of imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 2004;104(11):Abstract #4680.
104. McLean LA, Gathmann I, Capdeville R, et al. Pharmacogenomic
analysis of cytogenetic response in chronic myeloid leukemia patients treated
with imatinib.
Clinical
Cancer Research 2004;10(1 Pt 1):155-65.
105. Merx K, Muller MC, Kreil S, et al. Early reduction of
BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase
CML patients treated
with imatinib after failure of interferon alpha. Leukemia 2002;16(9):1579-83.
106. Monroy RH, Vargas-Viveros P, Cervera E, et al. Imatinib
Alone (IA) vs. Imatinib + Ara-C (IMAC): A randomized phase III clinical trial
for the treatment
of
early phase (EP) chronic myeloid leukemia (CML) Ph+. Preliminary report of
Mexican Cooperative Leukemia Group (GRUMELA). Blood 2004;104(11):Abstract #1015.
107. Moravcova J, Zmekova V, Klamova H, et al. Differences
and similarities in kinetics of BCR-ABL transcript levels in CML patients treated
with imatinib
mesylate for chronic or accelerated disease phase. Leukemia Research 2004;28(4):415-9.
108. Müller MC, Gattermann N, Lahaye T, et al. Dynamics
of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia
patients with
imatinib
or interferon alpha/ara-C. Leukemia 2003;17(12):2392-400.
109. Müller MC, Paschka P, LaHaye T, et al. Molecular
long-term surveillance of CML patients on imatinib therapy. Follow-up of German
patients treated within
the IRIS trial. Blood 2004;104(11):Abstract #1003.
110. National Cancer Institute. Chronic Myelogenous Leukemia
(PDQ®): Treatment:
Health Professional Version; 2005. [Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/CML/healthprofessional/allpages
September 23, 2005]
111. National Comprehensive Cancer Network. Chronic Myelogenous
Leukemia - Clinical Practice Guidelines in Oncology: Version 1.2006. [Accessed
at http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf
September 23, 2005.]
112. National Institute for Clinical Excellence. Guidance on
the use of imatinib for chronic myeloid leukaemia. London: National Institute
for Clinical Excellence
(NICE); 2003.
113. O'Brien S, Giles F, Talpaz M, et al. Results of triple
therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact
of adding imatinib to the
treatment sequence in patients with Philadelphia chromosome-positive chronic
myelogenous leukemia in early chronic phase. Cancer 2003;98(5):888-93.
114. O'Brien S, Guilhot F, Larson RA, et al. Imatinib compared
with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic
myeloid leukemia.
New England Journal of Medicine 2003;348(11):994-1004.
115. O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia
and myeloproliferative disease. 2004.
116. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration
of Philadelphia chromosome negative abnormal clones in patients with chronic
myelogenous leukemia
during
major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17(3):481-7.
117. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution
and lack of cytogenetic response are adverse prognostic factors for hematologic
relapse
of chronic
phase CML patients treated with imatinib mesylate. Blood 2004;103(2):451-5.
118. Olavarria E, Ottmann OG, Deininger MW, et al. Response
to imatinib in patients who relapse after allogeneic stem cell transplantation
for chronic
myeloid
leukemia. Leukemia 2003;17(9):1707-12.
119. Onida F, Ball G, Kantarjian H, et al. Characteristics
and outcome of patients with Philadelphia chromosome negative, BCR/ABL negative
chronic myelogenous
leukemia. Cancer 2002;95(8):1673-84.
120. Palandri F, Martinelli G, Amabile M, et al. Imatinib therapy
for chronic myeloid leukemia patients who relapse after allogeneic stem cell
transplantation: a
molecular analysis. Blood 2004;104(11):Abstract #4655.
121. Paschka P, Branford S, Lorentz C, et al. Comparison of "log
reduction from median pretherapeutic value" vs ratio BCR-ABL/ABL to express
the therapeutic response in CML patients. Blood 2004;104(11):Abstract #1013.
122. Paschka P, Muller MC, Merx K, et al. Molecular monitoring
of response to imatinib (Glivec) in CML patients pretreated with interferon
alpha. Low
levels
of residual
disease are associated with continuous remission. Leukemia 2003;17(9):1687-94.
123. Pasquini R, Clementino NC, Zanichelli MA, et al. Observational
study for evaluation of quality of life in patients with chronic myeloid leukemia
(CML)
in use of
Gleevec® (imatinib mesilate). Blood 2004;104(11):Abstract #2932.
124. Pautas C, Nicolini F, Cony-Makhoul P, et al. Imatinib
mesylate (IM), is an alternative to donor lymphocyte infusion (DLI) for chronic
myelogenous
leukemia
(CML) in relapse after allogeneic stem cell transplantation: a 3-year follow-up
report, on the Behalf of the Société Française de Greffe
de Moëlle et de Thérapie Cellulaire (SFGM-TC) and the France Intergroupe
de la Leucémie Myéloïde Chronique (Fi-LMC). Blood 2004;104(11):Abstract #1017.
125. Press RD, Love Z, Tronnes AA, et al. BCR-ABL RNA levels
at the time of a complete cytogenetic response (CCR) predict the duration of
CCR in imatinib-treated
chronic myeloid leukemia patients. Blood 2004;104(11):Abstract #1098.
126. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib
mesylate therapy may overcome the poor prognostic significance of deletions
of derivative chromosome
9 in patients with chronic myelogenous leukemia. Blood 2005;105(6):2281-6.
127. Radich J, Gooley T, Bensinger W, et al. HLA-matched related
hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan
and cyclophosphamide
preparative regimen. Blood 2003;102(1):31-5.
128. Robinson KA, Dickersin K. Development of a highly sensitive
search strategy for the retrieval of reports of controlled trials using PubMed. International
Journal of Epidemiology 2002;31(1):150-3.
129. Rosti G, Martinelli G, Bassi S, et al. Molecular response
to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004;103(6):2284-90.
130. Rousselot P, Legros L, Guilhot J, et al. A Phase I/II dose
escalating study of daunorubicin combined with imatinib mesylate and cytarabine
as induction
therapy for chronic myelogenous leukaemia in myeloid blast crisis. Preliminary
results of the AFR01 trial. Blood 2004;104(11):Abstract #1002.
131. Sacchi S, Kantarjian H, O'Brien S, et al. Chronic myelogenous
leukemia in nonlymphoid blastic phase. Cancer 1999;18(12):2632-41.
132. Savage D, Antman K. Imatinib mesylate—a new oral
targeted therapy. New
England Journal of Medicine 2002;346(9):683-93.
133. Savage D, Szydlo R, Chase A, et al. Bone marrow transplantation
for chronic myeloid leukaemia: the effects of differing criteria for defining
chronic phase
on probabilities of survival and relapse. British Journal of Haematology 1997;99(1):30-5.
134. Savage D, Szydlo R, Goldman JM. Clinical features at diagnosis
in 430 patients with chronic myeloid leukaemia seen at a referral centre over
a 16-year
period.
British Journal of Haematology 1997;96(1):111-6.
135. Sawyers CL. Chronic myeloid leukemia—Review Article. New
England Journal of Medicine 1999;340(17):1330-40.
136. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces
hematologic and cytogenetic responses in patients with chronic myelogenous
leukemia in
myeloid
blast crisis: results of a phase II study. Blood 2002;99(10):3530-9.
137. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase
domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor
imatinib (STI571)
in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117-25.
138. Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate
(STI571) in preparation for allogeneic hematopoietic stem cell transplantation
and donor
lymphocyte
infusions in patients with Philadelphia-positive acute leukemias. Leukemia
2003;17(2):290-7.
139. Silver RT, Talpaz M, Sawyers CL, et al. Four years of
follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase
(AP), or blast crisis
(BC)
chronic myeloid leukemia (CML) treated with imatinib in three large Phase II
trials. Blood 2004;104(11):Abstract #23.
140. Sinclair P, Nacheva E, Leversha M, et al. Large deletions
at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup
of patients
with chronic
myeloid leukemia. Blood 2000;95(3):738-43.
141. Sneed TB, Kantarjian H, Talpaz M, et al. The significance
of myelosuppression during therapy with imatinib mesylate in patients with
chronic myelogenous
leukemia in chronic phase. Cancer 2004;100(1):116-21.
142. Sokal J, Baccarani M, Russo D, et al. Staging and prognosis
in chronic myelogenous leukemia. Seminars in Hematology 1988;25(1):49-61.
143. Soverini S, Martinelli G, Amabile M, et al. Denaturing-HPLC-based
assay for detection of ABL mutations in chronic myeloid leukemia patients resistant
to
Imatinib. Clinical Chemistry 2004;50(7):1205-13.
144. Soverini S, Martinelli G, Rosti G, et al. ABL mutations
in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic
resistance
to imatinib
are associated with a greater likelihood of progression to blast crisis and
shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia.
Journal of Clinical Oncology 2005;23(18):4100-9.
145. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid
leukemia patients resistant to or intolerant of interferon alpha and subsequently
treated with
imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica
2003;88(7):762-8.
146. Stentoft J, Pallisgaard N, Kjeldsen E, et al. Kinetics
of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated
with STI571
measured by
quantitative real-time polymerase chain reaction. European Journal of Haematology
2001;67(5-6):302-8.
147. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate
as treatment for blastic transformation of Philadelphia chromosome positive
chronic myelogenous
leukemia. Haematologica 2003;88(11):1213-20.
148. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces
durable hematologic and cytogenetic responses in patients with accelerated
phase chronic myeloid
leukemia: results of a phase 2 study. Blood 2002;99(6):1928-37.
149. Thomas M, Irving J, Lennard A, et al. Validation of the
Hasford score in a demographic study in chronic granulocytic leukaemia. Journal
of Clinical Pathology
2001;54(6):491-3.
150. Thomazy VA, Kantarjian H, Imam M, et al. Use of Plasma
RNA for Real-Time Quantitative RT-PCR to Monitor Imatinib Therapy in Patients
with
Chronic Myeloid
Leukemia.
Blood 2004;104(11):Abstract #1099.
151. U.S. Food and Drug Administration. Gleevec approved for
first line treatment of chronic myeloid leukemia (CML). 2002. [Accessed at:
http://www.fda.gov/bbs/topics/NEWS/2002/NEW00860.html,
September 23, 2005]
152. Valeyrie L. , Bastuji-Garin S. , Revuz J. , et al. Adverse
cutaneous reactions to imatinib (ST1571) in Philadelphia chromosome-positive
leukemias:
A prospective
study of 54 patients. Journal of the American Academy of Dermatology 2003;48(2):201-6.
153. Vallespí T, Borrego M, Colomé D, et al.
Quantitative polymerase chain reaction (qPCR) at diagnosis and follow-up of
patients with chronic myeloid
leukemia in treatment with imatinib. Blood 2004;104(11):Abstract #4688.
154. van Rhee F, Szydlo R, Hermans J, et al. Long-term results
after allogeneic bone marrow transplantation for chronic myelogenous leukemia
in chronic phase:
a report from the Chronic Leukemia Working Party of the European Group for
Blood and Marrow Transplantation. Bone Marrow Transplantation 1997;20(7):553-60.
155. Wang L, Pearson K, Ferguson JE, et al. The early molecular
response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid
leukaemia.
British
Journal of Haematology 2003;120(6):990-9.
156. White DL, Saunders VA, Branford S, et al. The combination
of intrinsic sensitivity to imatinib and sokal prognostic score is strongly
predictive of
molecular
response in newly diagnosed CML patients treated with imatinib. Blood 2004;104(11):Abstract #1008.
157. Wu CJ, Neuberg D, Chillemi A, et al. Quantitative monitoring
of BCR/ABL transcript during STI-571 therapy. Leukemia & Lymphoma 2002;43(12):2281-9.
158. Xie Y, Davies S, Xiang Y, et al. Trends in leukemia incidence
and survival in the United States (1973-1998). 2003;97(9):2229-35.
Return to Contents
Proceed to Next Section
540 Gaither Road Rockville, MD 20850